Breaking News

BREAKING: 22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions

22 U.S. Senate Democrats Want Answers from PhRMA About its Members’ 340B Actions

Twenty-two Democratic U.S. senators asked Pharmaceutical Research and Manufacturers of America (PhRMA) today to inform them by no later than Sept. 29 “regarding steps being taken by

Read More »

In Partisan U.S. House, Consensus Emerges Over Manufacturer 340B Actions

Note from Publisher and CEO Ted Slafsky: I encourage you to read today’s sponsored content article from 340B Report sponsor Trellis Rx about a Sept. 22 panel discussion on recent manufacturer actions in the contract pharmacy space as well as mitigation

Read More »

Breaking News

BREAKING: More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately

More than Half of the U.S. House Asks Azar to Address Drug Makers’ 340B Actions Immediately

More than half of the U.S. House today told U.S. Health and Human Services (HHS) Secretary Alex Azar “it is imperative that immediate action

Read More »

Lilly’s 340B Contract Pharmacy Ban Has Crept Into In-House Pharmacies

Note from the Publisher and CEO Ted Slafsky: I want to acknowledge this date, Sept. 11, and its solemn importance to our country. We honor those who were lost 19 years ago today and continue to cherish the great work of

Read More »

Health Centers Are Preparing to Sue Over Drug Makers' 340B Actions

Health Centers Are Preparing to Sue Over Drug Makers’ 340B Actions

The National Association of Community Health Centers (NACHC) “is preparing legal action” in response to drug manufacturers’ recent unilateral moves to stop providing reduced 340B pricing on their products

Read More »

Breaking News

BREAKING: House Democratic Committee Chairs Say Drug Companies’ Actions Could Put 340B on “Treacherous Path”

House Democratic Committee Chairs Say Drug Companies’ Actions Could Put 340B on “Treacherous Path”

Letting drug manufacturers “pick and choose” which 340B program requirements they will comply with “could set us on a treacherous path where program participants might disregard

Read More »

White House Fast-Tracking 340B Executive Order on Insulin, Epinephrine


Note from the Publisher and CEO Ted Slafsky:  We are still collecting reaction from our breaking story last night but have plenty of other news and information in today’s issue. Due to the Labor Day holiday, we

Read More »

Breaking News

BREAKING: HRSA is Investigating Whether Manufacturer Policies to Restrict 340B Pricing at Contract Pharmacies Violates Statute

HRSA is Investigating Whether Manufacturer Policies to Restrict 340B Pricing at Contract Pharmacies Violates Statute

In a major development, the Health Resources and Services Administration (HRSA) has told 340B Report that it is investigating whether recent manufacturer policies to restrict

Read More »

Breaking News

BREAKING: Eli Lilly Comment on Today's Actions

After publication, 340B Report received the following comment from Eli Lilly and Co. on its actions that we reported on today:

Report after report shows 340B is not working for patients and needs reform. We support recent executive action on

Read More »

Eli Lilly Dramatically Escalates Efforts to Restrict Access to 340B Pricing


Note from the Publisher and CEO Ted Slafsky:  Bronwyn Mixter is filling in for Tom Mirga this week.  If you have story ideas or tips, feel free to reach her at bronwyn.mixter@340breport.com or 703-403-5926. We’re pleased to include

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live